Literature DB >> 22091537

Development of neutralizing antibody responses in muskellunge, Esox masquinongy (Mitchill), experimentally exposed to viral haemorrhagic septicaemia virus (genotype IVb).

E V Millard1, M Faisal.   

Abstract

A complement-dependent 50% plaque neutralization test was used to assess the neutralizing antibody response in sera of muskellunge, Esox masquinongy, experimentally infected with viral haemorrhagic septicaemia virus (VHSV, genotype IVb) by immersion. Groups of muskellunge were challenged with varying concentrations of VHSV: Group 1 with 10(2) plaque-forming units (pfu) mL(-1) , Group 2 with 4 × 10(3)  pfu mL(-1) , Group 3 with 10(5)  pfu mL(-1) and Group 4 with 0 pfu mL(-1) . The fish were held at a temperature of 11 ± 1 °C and were sampled over a 20-week period. Neutralizing antibodies were not detected in sera of any of the negative control fish throughout the study. Low neutralizing titres were detected in Groups 1-3 by 6 days post-infection (p.i.). Neutralizing titres of ≥80 [corrected]. were not detected again until 3, 4 and 7 weeks p.i. for Groups 2, 3 and 1, respectively, with peak titres for those groups occurring 16, 11 and 17 weeks p.i., respectively. VHSV was detected in serum for up to 11 weeks p.i. Results of this study show that survivors can be detected by a serological technique, despite being virus negative. This may benefit the investigation of VHSV IVb distribution in the Great Lakes and the study of host immune responses to this emerging sublineage.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22091537     DOI: 10.1111/j.1365-2761.2011.01318.x

Source DB:  PubMed          Journal:  J Fish Dis        ISSN: 0140-7775            Impact factor:   2.767


  3 in total

1.  In vivo and in vitro phenotypic differences between Great Lakes VHSV genotype IVb isolates with sequence types vcG001 and vcG002.

Authors:  Sierra M Imanse; Emily R Cornwell; Rodman G Getchell; Gael Kurath; Paul R Bowser
Journal:  J Great Lakes Res       Date:  2014-12-01       Impact factor: 2.480

2.  Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus.

Authors:  Anna Wilson; Tony Goldberg; Susan Marcquenski; Wendy Olson; Frederick Goetz; Paul Hershberger; Lucas Hart; Kathy Toohey-Kurth
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

3.  Spread of the emerging viral hemorrhagic septicemia virus strain, genotype IVb, in Michigan, USA.

Authors:  Mohamed Faisal; Megan Shavalier; Robert K Kim; Elena V Millard; Michelle R Gunn; Andrew D Winters; Carolyn A Schulz; Alaa Eissa; Michael V Thomas; Martha Wolgamood; Gary E Whelan; James Winton
Journal:  Viruses       Date:  2012-05-03       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.